ECSP22066085A - ANTICUERPOS CONTRA LA INTEGRINA alfaVß8 PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD RENAL - Google Patents
ANTICUERPOS CONTRA LA INTEGRINA alfaVß8 PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD RENALInfo
- Publication number
- ECSP22066085A ECSP22066085A ECSENADI202266085A ECDI202266085A ECSP22066085A EC SP22066085 A ECSP22066085 A EC SP22066085A EC SENADI202266085 A ECSENADI202266085 A EC SENADI202266085A EC DI202266085 A ECDI202266085 A EC DI202266085A EC SP22066085 A ECSP22066085 A EC SP22066085A
- Authority
- EC
- Ecuador
- Prior art keywords
- alphavß8
- integrin
- kidney
- kidney disease
- tissue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporcionan métodos y composiciones para tratar una enfermedad renal, tal como enfermedad renal crónica (CKD), en los que los métodos y composiciones comprenden anticuerpos o un fragmento de unión al antígeno de estos que se unen de manera específica y selectiva a la integrina alfavß8 humana, de la que se descubrió, como se describe, que presenta una expresión muy elevada en células y tejido renales y, en particular, tejido renal enfermo o fibrótico. Los anticuerpos contra la integrina alfavß8 divulgados se unen a la integrina alfavß8 humana en el riñón y bloquean la activación de TGF-ß; a partir de su forma latente en el tejido renal. Los anticuerpos contra alfavß8 en los métodos divulgados reducen, atenúan o anulan la fibrosis renal, que está asociada con la actividad de la integrina alfavß8 y TGF-ß; en el tejido renal. Los anticuerpos y métodos divulgados tratan de manera eficaz la enfermedad renal, en particular, la fibrosis asociada con la enfermedad renal, tal como CKD, en individuos que lo necesiten.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062966258P | 2020-01-27 | 2020-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22066085A true ECSP22066085A (es) | 2022-09-30 |
Family
ID=74561850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202266085A ECSP22066085A (es) | 2020-01-27 | 2022-08-23 | ANTICUERPOS CONTRA LA INTEGRINA alfaVß8 PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD RENAL |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230112035A1 (es) |
EP (1) | EP4096785A1 (es) |
JP (1) | JP2023511686A (es) |
KR (1) | KR20220132567A (es) |
CN (1) | CN115151305A (es) |
AR (1) | AR121193A1 (es) |
AU (1) | AU2021213403A1 (es) |
BR (1) | BR112022014633A2 (es) |
CA (1) | CA3167390A1 (es) |
CL (1) | CL2022001999A1 (es) |
CO (1) | CO2022011661A2 (es) |
CR (1) | CR20220392A (es) |
EC (1) | ECSP22066085A (es) |
IL (1) | IL294814A (es) |
MX (1) | MX2022009165A (es) |
TW (1) | TW202140554A (es) |
WO (1) | WO2021151889A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024056668A1 (en) | 2022-09-12 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
CN117126282B (zh) * | 2023-10-26 | 2024-01-12 | 迈威(上海)生物科技股份有限公司 | 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用 |
CN117143241B (zh) * | 2023-10-26 | 2024-02-23 | 迈威(上海)生物科技股份有限公司 | 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
EP4219560A3 (en) * | 2010-02-18 | 2023-08-23 | The Regents of The University of California | Integrin alpha v beta 8 neutralizing antibody |
EP2744823B1 (en) | 2011-08-17 | 2017-08-02 | The Regents of the University of California | Antibodies that bind integrin alpha-v beta-8 |
JP2017522289A (ja) | 2014-06-17 | 2017-08-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 改善されたα−Vβ−8抗体 |
WO2018227018A1 (en) * | 2017-06-07 | 2018-12-13 | Silverback Therapeutics, Inc. | Antibody conjugates of immune-modulatory compounds and uses thereof |
-
2021
- 2021-01-13 TW TW110101209A patent/TW202140554A/zh unknown
- 2021-01-26 AU AU2021213403A patent/AU2021213403A1/en active Pending
- 2021-01-26 US US17/759,388 patent/US20230112035A1/en active Pending
- 2021-01-26 EP EP21703839.7A patent/EP4096785A1/en active Pending
- 2021-01-26 CA CA3167390A patent/CA3167390A1/en active Pending
- 2021-01-26 JP JP2022545136A patent/JP2023511686A/ja active Pending
- 2021-01-26 CR CR20220392A patent/CR20220392A/es unknown
- 2021-01-26 WO PCT/EP2021/051753 patent/WO2021151889A1/en active Application Filing
- 2021-01-26 KR KR1020227028722A patent/KR20220132567A/ko active Search and Examination
- 2021-01-26 MX MX2022009165A patent/MX2022009165A/es unknown
- 2021-01-26 BR BR112022014633A patent/BR112022014633A2/pt unknown
- 2021-01-26 CN CN202180010557.1A patent/CN115151305A/zh active Pending
- 2021-01-26 IL IL294814A patent/IL294814A/en unknown
- 2021-01-27 AR ARP210100199A patent/AR121193A1/es unknown
-
2022
- 2022-07-25 CL CL2022001999A patent/CL2022001999A1/es unknown
- 2022-08-18 CO CONC2022/0011661A patent/CO2022011661A2/es unknown
- 2022-08-23 EC ECSENADI202266085A patent/ECSP22066085A/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202140554A (zh) | 2021-11-01 |
CR20220392A (es) | 2022-09-07 |
CL2022001999A1 (es) | 2023-01-27 |
CO2022011661A2 (es) | 2022-08-30 |
KR20220132567A (ko) | 2022-09-30 |
CN115151305A (zh) | 2022-10-04 |
IL294814A (en) | 2022-09-01 |
JP2023511686A (ja) | 2023-03-22 |
EP4096785A1 (en) | 2022-12-07 |
BR112022014633A2 (pt) | 2022-09-13 |
CA3167390A1 (en) | 2021-08-05 |
AU2021213403A1 (en) | 2022-09-15 |
AR121193A1 (es) | 2022-04-27 |
MX2022009165A (es) | 2022-08-16 |
WO2021151889A1 (en) | 2021-08-05 |
US20230112035A1 (en) | 2023-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP22066085A (es) | ANTICUERPOS CONTRA LA INTEGRINA alfaVß8 PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD RENAL | |
PE20081635A1 (es) | Agentes para suprimir la reaccion de rechazo cronica | |
EA202091846A1 (ru) | Соединения с активностью, индуцирующей ферроптоз, и способы их применения | |
AR065589A1 (es) | Prediccion de respuesta a un inhibidor her | |
CO6341486A2 (es) | Tratamiento y profilaxis de amiloidosis | |
EA200901211A1 (ru) | Антигены белка с5 и их применение | |
GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
UY28287A1 (es) | Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis | |
BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
ECSP15005280A (es) | Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos | |
EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
BR112017022323A2 (pt) | método para tratar doença do enxerto contra hospedeiro, uso de um composto, e, kit. | |
BR112022024483A2 (pt) | Métodos para tratar mieloma múltiplo | |
AR082313A1 (es) | Composicion farmaceutica de combinacion para tratar enfermedades o condiciones asociadas una enfermedad o condicion respiratoria | |
UY37967A (es) | Compuestos y métodos para la reducción de la expresión de snca | |
EA201992326A1 (ru) | Композиции и способы оказания направленного воздействия на альфа-v бета-3-положительные раковые стволовые клетки (csc) и лечения (avb3) лекарственно-устойчивых видов рака | |
BR112022025198A2 (pt) | Formas sólidas do inibidor de apol1 e uso das mesmas | |
BR112022004861A2 (pt) | Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro | |
BR112022002579A2 (pt) | Anticorpos contra ilt2 e uso dos mesmos | |
ECSP10010716A (es) | Combinaciones farmaceuticas. | |
EA201591522A1 (ru) | Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов | |
EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
EA201491048A1 (ru) | Соединения двухцепочечных рнк к casp2 и их применение | |
BR102018074037A2 (pt) | composto para direcionar entidades moleculares para o domínio intracelular de células neoplásicas, ingrediente farmacêutico ativo compreendendo o referido composto, composição farmacêutica, método para o diagnóstico, prognóstico e/ou tratamento de câncer |